A Message From NCI: “We Deeply Regret The Need To Eliminate This Program.” AP4 Applicants And Corporate Partners Spent Years, Money, Before NCI Pulled The Plug On Novel Public-Private Partnerships. Von Eschenbach Called AP4 “A New Paradigm” For Drug Development. NCI Executive Committee “Prioritized” Programs.
Also NSABP’s STAR Trial Finds Raloxifene Equivalent To Tamoxifen For Breast Cancer Risk Reduction.
